Chronic inflammation is a hallmark of cancer cachexia in both patients and preclinical
models. Cachexia is prevalent in roughly 80% of cancer patients and accounts for up to 20 …

Cancer cachexia is a complex multi‐organ catabolic syndrome that reduces mobility,
increases fatigue, decreases the efficiency of therapeutic strategies, diminishes the quality of …

Cachexia is a wasting syndrome characterized by pronounced skeletal muscle loss. In
cancer, cachexia is associated with increased morbidity and mortality and decreased …

Age-related loss of skeletal muscle mass and contractile dysfunction, or sarcopenia, reduces
independence and quality of life in the elderly and leads to increased risk of comorbidities …

The term fatigue is used to describe a distressing and persistent symptom of physical and/or
mental tiredness in certain clinical populations, with distinct but ultimately complex …

Breast cancer represents the most commonly diagnosed cancer while neoadjuvant and
adjuvant chemotherapies are extensively used in order to reduce tumor development and …

ABSTRACT The Forkhead box O (FoxO) transcription factors are activated, and necessary
for the muscle atrophy, in several pathophysiological conditions, including muscle disuse …

Cancer cachexia is a syndrome characterized by loss of skeletal muscle mass, inflammation,
anorexia and anemia, contributing to patient fatigue and reduced quality of life. In addition to …

Cachexia, the unintentional loss of body weight, is prevalent in many cancer types, and the
associated skeletal muscle mass depletion increases patient morbidity and mortality. While …

Background Evidence from cachectic cancer patients and animal models of cancer cachexia
supports the involvement of Forkhead box O (FoxO) transcription factors in driving cancer …